

Primary	Description	Lead REG	Resea Primary Investigator	ENCePP Referr	Funding status
<b>MANUSCRIPT PHASE (2)</b>					
Analysis complete and manuscript in progress					
<b>COPD</b>					
PIF in COPD	A prospective trial to assess the role of PIF in predicting COPD exacerbations	Valeria Perugini	Omar Usmani	<a href="#">EUPAS34689</a>	Boehringer Ingelheim
<b>Environment, Epidemiology &amp; Airways</b>					
Expert opinion on the impact of inhaler choice on climate change and patient outcomes: Position statement	An REG position statement on inhaler choice	Graham Lough	Omar Usmani		Chiesi, Kindeva, Astrazeneca and Boehringer Ingelheim
<b>IN PROGRESS (5)</b>					
Protocol finalised and study underway					
<b>COPD</b>					
PIF in COPD	A prospective trial to assess the role of PIF in predicting COPD exacerbations	Valeria Perugini	Omar Usmani	<a href="#">EUPAS34689</a>	Boehringer Ingelheim
PREdiCting the risk for first COPD Severe EXacerbation (PRECISE- X)	Development of a risk prediction model for first severe COPD exacerbation.	Valeria Perugini	Bernardino Alcazar Navarrete	EUPAS50803	Funded by AZ
Effects of triple pharmacological therapy on post-discharge outcomes in patients with COPD	The study aims to investigate the frequency and risk factors for readmission and early exacerbations in patients discharged after an exacerbation of COPD and also the impact of pharmacologic treatment focusing on its efficacy in terms of prolonging the time to the next admission, lung function, symptoms and quality of life.	Valeria Perugini	Chin Kook Rhee		Chiesi
<b>Child Health</b>					
Severe Asthma in Children in Primary Care	Database study on the prevalence and incidence of severe asthma in children in primary care, and the incidence and prevalence of referral to an asthma specialist.	Valeria Perugini	Steve Turner	EUPAS50650	Funded by Sanofi
<b>Adherence</b>					
Adherence monitoring and management	Literature reviews to assess how adherence is currently incorporated within guidelines and to determine how adherence can be monitored and managed with personalised medicine.	Valeria Perugini	Sinthia Bosnic-Anticevich		TEVA
<b>Cost effectiveness</b>					
A global evaluation of the economic impact of time to initiation of biologic treatment of severe asthma patients	This study aims to identify the effect of time to initiation of biologic treatment of severe asthma patients on lifetime cost and disease burden at both global and national levels.	Graham Lough	Brett McQueen	EUPAS10000033	AZ funding secured.
<b>ACTIVE DEVELOPMENT (5)</b>					
Currently in development and seeking funding					
<b>IPF/ILD</b>					
Towards Standardisation in IPF / PPF Registry Data – Project 1: Identifying Key Variables through a Global Prioritisation Task	Identification of key variables to include in IPF / PPF registry and exploration of similarities and differences in diagnostic / prognostic priorities across different regions. Development of a registry standardisation template.	Graham Lough	TBA		Seeking funding
Towards Standardisation in IPF / PPF Registry Data – Project 2: Identifying Data Elements for Disease Management	IPF / PPF registry data population and internal validation of disease outcomes. Refinement of key variables.	Graham Lough	TBA		Seeking funding
Towards Standardisation in IPF / PPF Registry Data – Project 3: Development of a Global Composite Staging System for IPF / PPF Disease Progression	Creation of a comprehensive staging system for IPF and PPF that can be applied globally. Evaluate regional variations; and assessment of regional differences and commonalities in the stages of disease progression to understand geographical variations and enhance the staging system's applicability. Validation of the global registry.	Graham Lough	TBA		Seeking funding
Genetic Determinants of Pulmonary Hypertension in Interstitial Lung Disease: Uncovering Pathways for Early Detection and Precision Medicine	Investigate overlap and distinction of genes associated with Group 3 pulmonary hypertension in ILD patients to highlight unique genetic markers for targeted screening and therapeutic interventions.	Graham Lough	Pilar Rivera-Ortega		Seeking funding
Genomic Testing for Interstitial Lung Disease: An International Delphi survey and global mapping exercise	Identification of centres around the world where genomic testing is offered for ILD cases and identify the core features for establishing a Genetics-ILD service, taking into account current practices and disparities in access to genomic testing and genetic counselling.	Graham Lough	Pilar Rivera-Ortega		Seeking funding
<b>Other diseases</b>					
<b>Vaccines</b>					
Vaccine Uptake and Exacerbations in COPD Patients: A Retrospective Study	This project will evaluate the impact of pneumococcal, COVID and influenza vaccination on exacerbation rates, comparing vaccinated and unvaccinated COPD patients and examine vaccine uptake trends in COPD patients.	Graham Lough	Nicolas Roche		Seeking funding
Vaccine Uptake in Chronic Respiratory Patients: A Retrospective Study Across At-Risk Respiratory Diseases	This project will evaluate the impact of pneumococcal, COVID, pertussis and influenza vaccination on hospitalisations / exacerbations, comparing vaccinated and unvaccinated high-risk chronic respiratory patients and examine vaccine uptake trends in high-risk chronic respiratory patients.	Graham Lough	Nicolas Roche		Seeking funding
<b>Database and Coding</b>					
Standardisation of respiratory definitions and outcomes using real world data	The project will establish definitions and standards for use of European RWD sources while monitoring and improving their mapping to common data models.	Valeria Perugini	Jennifer Quint		
Assessing the interplay between T2D and COPD	The study is designed to assess the mortality risk and disease progression among people with both T2D and COPD	Valeria Perugini	Jennifer Quint		
<b>IN DISCUSSION (4)</b>					
Discussed as future ideas					
<b>COPD</b>					
Low Dose Macrolides in COPD	Database study to determine prevalence, characteristics and outcomes in of those prescribed low dose macrolides. Comparisons with ICS treatment.	Valeria Perugini	Therese Lapperre & Marc Miravittles		
<b>Allergy</b>					
Allergen Immunotherapy Missed Opportunities and Resource Expenditure in the UK (AIMORE-UK)	Retrospective / cost study to identify clinical and costs associated with underutilisation of AIT in the UK.	Graham Lough	Désirée Larenas-Linnemann		
Persistent to Chronic Rhinosinusitis: From Presentation to Referral (P2C-RS)	Retrospective / cost study to evaluate the healthcare and cost burden of delayed diagnosis and referrals of persistent rhinosinusitis and associated comorbidities.	Graham Lough	Désirée Larenas-Linnemann		
<b>Severe Asthma &amp; Biomarkers</b>					
Biomarkers to predict outcome of biologic treatment	Using data from various registries the study would look at blood eos, FeNO and IgE changes in response to biologic treatment, including the interactions between different biomarkers and comorbidities to determine whether we can predict biologic treatment response	Valeria Perugini	Leif Bjerner		
<b>ON HOLD 2025</b>					
<b>Allergy</b>					
Secondary Prevention in Moderate Allergic Asthma with AIT	Exploratory prospective non interventional study to examine the impact of AIT on allergic asthma	Graham Lough	Désirée Larenas-Linnemann		Seeking funding
Exploring the Effects of Inhaler Switching on Exacerbations in Asthma / COPD patients: Insights from Primary Care	Investigate patterns of inhaler switching among asthma and COPD patients and association between switching and exacerbation rates / healthcare resource utilisation and identifying factors influencing clinical outcomes.	Graham Lough	Jenni Quint		Seeking funding
Mapping ILD Diagnosis: Risk, Referrals, and Missed Cases in Primary/Secondary Care in the UK	The project aims to analyse referral patterns to ILD specialist centres / tertiary care from primary and secondary care to identify potentially missed and undiagnosed ILD patients within the healthcare system, and develop a risk prediction model to identify patients at risk of ILD.	Graham Lough	?		Seeking funding
Predicting pulmonary hypertension risk in ILD patients	Development of a risk prediction model for identifying the risk of pulmonary hypertension development in ILD patients.	Graham Lough	Pilar Rivera-Ortega		Seeking funding

**ON HOLD 2021****Adherence**

Adherence in asthmatics and COVID-19 outcomes	Investigation of whether adherence to asthma medication is protective for severe COVID-19	Valeria Perugini	Eric van Ganse	Seeking funding
---	---	------------------	----------------	-----------------

**Database and Coding**

Mapping of respiratory information in the Common Data Model	Letter considering how respiratory variables are being mapped to the CDM, including where the mapping appropriate, issues, challenges and recommendations and best practices going forward.	Valeria Perugini	Katia Verhamme	REG
---	---	------------------	----------------	-----

Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes (TORPEDO)- PHASE 2	Survey to determine a list of current databases and which of the minimum variables from Phase 1 they contain, and a tool for the website to add selection of variables for prospective studies	Valeria Perugini	Job van Boven & Katia Verhamme	Unfunded
--	--	------------------	--------------------------------	----------

**Child Health**

Step down of ICS in paediatric asthma patients	A database study to assess the effects of step down or withdrawal of inhaled corticosteroids in children	Valeria Perugini	Steve Turner & Nicolas Roche	Funded by a charitable donation
--	--	------------------	------------------------------	---------------------------------

**ON HOLD 2022 (4)****Environment, Epidemiology & Airways**

Expert opinion on the impact of inhaler choice on climate change and patient outcomes: Phase 2 (delphi)	A Delphi study on priorities of experts of inhaler choice	Graham Lough	Omar Usmani	Chiesi, Kindeva, Astrazeneca and Boehringer Ingelheim
---	---	--------------	-------------	---

**Technology**

A study of the real-world acceptability and usability of Enerzair® Breezhaler® + Propeller® sensor + app in uncontrolled asthma patients	A prospective study to describe engagement, compliance, acceptability and usability of the Enerzair® Breezhaler®, Propeller® digital sensor and Propeller Health® app package in uncontrolled asthma patients, as well factors associated with better patient outcomes, inhaler technique and adherence	Graham Lough	Esther Metting	Novartis to confirm.
--	---	--------------	----------------	----------------------